Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
HL301 vs Umkamin in Acute Bronchitis
NCT03654196Phase 3Completed
- Sponsor
- Hanlim Pharm
- Start
- Mar 2018
- Primary completion
- Sep 2018
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 3 trial of HL301 in acute bronchitis, sponsored by Hanlim Pharm. Started Mar 2018; status: completed.
02
Drugs
HL301
03
Conditions
acute bronchitis
Beyond the preview
Go deeper on NCT03654196.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03654196.